Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 4
2005 1
2006 1
2007 1
2008 1
2011 6
2012 1
2013 1
2014 2
2015 2
2016 2
2017 2
2018 1
2019 5
2020 3
2021 8
2022 5
2023 6
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

51 results

Results by year

Filters applied: . Clear all
Page 1
Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study.
Tison A, Quéré G, Misery L, Funck-Brentano E, Danlos FX, Routier E, Robert C, Loriot Y, Lambotte O, Bonniaud B, Scalbert C, Maanaoui S, Lesimple T, Martinez S, Marcq M, Chouaid C, Dubos C, Brunet-Possenti F, Stavris C, Chiche L, Beneton N, Mansard S, Guisier F, Doubre H, Skowron F, Aubin F, Zehou O, Roge C, Lambert M, Pham-Ledard A, Beylot-Barry M, Veillon R, Kramkimel N, Giacchero D, De Quatrebarbes J, Michel C, Auliac JB, Gonzales G, Decroisette C, Le Garff G, Carpiuc I, Vallerand H, Nowak E, Cornec D, Kostine M; Groupe de Cancérologie Cutanée, Groupe Français de Pneumo-Cancérologie, and Club Rhumatismes et Inflammations. Tison A, et al. Among authors: mansard s. Arthritis Rheumatol. 2019 Dec;71(12):2100-2111. doi: 10.1002/art.41068. Epub 2019 Oct 21. Arthritis Rheumatol. 2019. PMID: 31379105
First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401.
Dummer R, Corrie P, Gutzmer R, Meniawy TM, Del Vecchio M, Lebbé C, Guida M, Dutriaux C, Dreno B, Meyer N, Ferrucci PF, Dalle S, Khattak MA, Grob JJ, Briscoe K, Larkin J, Mansard S, Lesimple T, Guidoboni M, Sabatini S, Richtig E, Herbst R, Lobo M, Askelson M, Ascierto PA, Maio M. Dummer R, et al. Among authors: mansard s. J Clin Oncol. 2023 Aug 10;41(23):3917-3929. doi: 10.1200/JCO.22.02199. Epub 2023 Jun 12. J Clin Oncol. 2023. PMID: 37307514 Clinical Trial.
Image Gallery: Unilateral eyebrow depigmentation.
Amini Adle M, Chastagner M, Mansard S, Dalle S. Amini Adle M, et al. Among authors: mansard s. Br J Dermatol. 2019 Apr;180(4):e107. doi: 10.1111/bjd.17638. Br J Dermatol. 2019. PMID: 30933341 No abstract available.
[Melanoma of the penis: 6 cases].
Orlandini V, Kolb F, Spatz A, Court B, Ortoli JC, Sabourin C, Wechsler J, Mansard S, Souteyrand P, Arigon V, Andry-Benzaquen P, Avril MF. Orlandini V, et al. Among authors: mansard s. Ann Dermatol Venereol. 2004 Jun-Jul;131(6-7 Pt 1):541-4. doi: 10.1016/s0151-9638(04)93665-4. Ann Dermatol Venereol. 2004. PMID: 15318136 Review. French.
Response to BRAF and MEK Inhibitors in BRAF Thr599dup-Mutated Melanoma.
Oberlé M, Jamme P, Mansard S, Machet L, Hervieu A, Kramkimel N, Greliak A, Jarrousse AS, Derangère V, Dudoignon D, Descarpentries C, Mortier L. Oberlé M, et al. Among authors: mansard s. JCO Precis Oncol. 2022 Mar;6:e2100417. doi: 10.1200/PO.21.00417. JCO Precis Oncol. 2022. PMID: 35319964 No abstract available.
Long term activity of vemurafenib in cancers with BRAF mutations: the ACSE basket study for advanced cancers other than BRAFV600-mutated melanoma.
Blay JY, Cropet C, Mansard S, Loriot Y, De La Fouchardière C, Haroche J, Topart D, Tougeron D, You B, Italiano A, Le Brun-Ly V, Ferrero JM, Penel N, Fabbro M, Troussard X, Malka D, Ray-Coquard I, Leboulleux S, Fléchon A, Maubec E, Charles J, Dalle S, Taieb S, Garcia GCTE, Mandache AM, Colignon N, Gavrel M, Nowak F, Hoog Labouret N, Mahier Aït Oukhatar C, Gomez-Roca C. Blay JY, et al. Among authors: mansard s. ESMO Open. 2023 Dec;8(6):102038. doi: 10.1016/j.esmoop.2023.102038. Epub 2023 Nov 1. ESMO Open. 2023. PMID: 37922690 Free PMC article.
Clostridium difficile infection and immune checkpoint inhibitor-induced colitis in melanoma: 18 cases and a review of the literature.
Vuillamy C, Arnault JP, Fumery M, Mortier L, Monestier S, Mansard S, Bens G, Duval-Modeste AB, Funck-Brentano E, Jeudy G, Machet L, Chaby G, Dadban A, Lok C; Groupe de Cancérologie Cutanée de la Société Française de Dermatologie. Vuillamy C, et al. Among authors: mansard s. Melanoma Res. 2023 Jun 1;33(3):192-198. doi: 10.1097/CMR.0000000000000878. Epub 2023 Mar 27. Melanoma Res. 2023. PMID: 36995276 Free PMC article. Review.
Vismodegib efficacy in unresectable trichoblastic carcinoma: A multicenter study of 16 cases.
Duplaine A, Beylot-Barry M, Mansard S, Arnault JP, Grob JJ, Maillard H, Saiag P, Poulalhon N, Cribier B, Mortier L, Battistella M, Jouary T. Duplaine A, et al. Among authors: mansard s. J Am Acad Dermatol. 2022 Jun;86(6):1365-1366. doi: 10.1016/j.jaad.2021.05.024. Epub 2021 May 27. J Am Acad Dermatol. 2022. PMID: 34052337 No abstract available.
Phase I study of [131I] ICF01012, a targeted radionuclide therapy, in metastatic melanoma: MELRIV-1 protocol.
Thivat E, Rouanet J, Auzeloux P, Sas N, Jouberton E, Levesque S, Billoux T, Mansard S, Molnar I, Chanchou M, Fois G, Maigne L, Chezal JM, Miot-Noirault E, D'Incan M, Durando X, Cachin F. Thivat E, et al. Among authors: mansard s. BMC Cancer. 2022 Apr 15;22(1):417. doi: 10.1186/s12885-022-09495-3. BMC Cancer. 2022. PMID: 35428211 Free PMC article.
51 results